Company profile
CERUS CORP
NASDAQ:CERSMedical/Dental Instruments
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02310412 | phase2 | completed | 2014-12-01 | 2015-05-01 | Cerus Corporation | A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma |
| NCT02295501 | phase1 | terminated | 2014-12-01 | 2020-12-01 | Cerus Corporation | A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease |
| NCT02653443 | phase2 | terminated | 2015-12-01 | 2016-05-01 | Cerus Corporation | A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study |
| NCT01711346 | phase2 | completed | 2012-10-01 | 2014-07-01 | Cerus Corporation | A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells |
| NCT01716923 | phase3 | completed | 2013-04-01 | 2014-07-01 | Cerus Corporation | Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia |
FDA applications (0)
No records yet.